Nant Capital Discloses 19.9% Stake in PDS Biotech with $10M Milestone Tranche and PDS0101 License Option
PDSB has more than doubled off its 52-week low of $0.195.
Summary
Nant Capital's 13D discloses a 19.9% stake in PDS Biotech, including a $10M milestone tranche contingent on FDA submission of a PDS0301 Phase 3 protocol, and a $25,000 option for exclusive negotiation rights to the PDS0101 program.
Key Events · Ownership and Investor Activity · PDSB
-
Nant Capital Acquires 19.9% Stake
Nant Capital purchased 13,005,334 shares of Common Stock and 22,392,896 Pre-Funded Warrants at the Initial Closing, plus 17,699,115 Common Warrants, giving it beneficial ownership of 20,336,335 shares (19.9% of 81,856,307 outstanding).
-
$10M Milestone Tranche Contingent on FDA Submission
At the Milestone Closing, Nant Capital will purchase $10,000,000 of additional securities at $0.22 per share (or $0.21967 per Pre-Funded Warrant), triggered by submission of a registrational Phase 3 protocol for PDS0301 to the FDA.
-
PDS0101 License Option for $25,000
NantWorks paid $25,000 for a one-year exclusive right to negotiate an exclusive license for all rights to the PDS0101 program, which PDS Biotech discontinued in August 2026.
-
Board Designation Rights
While Nant Capital owns ≥15% of outstanding shares, it may designate two directors to PDS Biotech's board, including Patrick Soon-Shiong, who was appointed on September 14, 2026.
Analysis · PDSB · Life Sciences
This 13D reveals the full structure of Nant Capital's investment in PDS Biotech, including a $10 million contingent milestone tranche tied to FDA submission of a Phase 3 protocol for PDS0301, and a one-year exclusive negotiation right for the discontinued PDS0101 program for just $25,000. The filing confirms Nant Capital holds 19.9% of the company — the maximum allowed under the beneficial ownership blocker — with board designation rights for two directors. Against the backdrop of PDS Biotech's going concern warning, $5.6M cash balance, and Nasdaq delisting risk, this investment provides critical near-term funding but also gives Nant Capital significant influence over the company's strategic direction, including potential control of the PDS0101 asset.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.1M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.